Detection and monitoring of the BCR-ABL transcripts are essential for CML diagnosis and evaluation of patient's response to treatment with tyrosine kinase inhibitors such as Imatinib [10]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.